1. Transforming growth factor-beta and its implication in the malignancy of gliomas

   • Laurent-Olivier Roy
   • Marie-Belle Poirier
   • David Fortin

   Review 05 March 2014 Pages: 1 - 14

   

2. The status of radioimmunotherapy in CD20+ non-Hodgkin’s lymphoma

   • Evan D. Read
   • Peter Eu
   • Terrence J. Piva

   Review 29 May 2014 Pages: 15 - 26

   

3. QT_c prolongation induced by targeted biotherapies used in clinical practice and under investigation: a comprehensive review

   • Marzia Locatelli
   • Carmen Criscitiello
   • Giuseppe Curigliano

   Review 27 June 2014 Pages: 27 - 43

   

4. Hypertension among patients with renal cell carcinoma receiving axitinib or sorafenib: analysis from the randomized phase III AXIS trial

   • Brian I. Rini
   • David I. Quinn
   • Robert J. Motzer

   Original Research Open access 05 March 2014 Pages: 45 - 53

   

5. An observational cohort study of bevacizumab and chemotherapy in metastatic colorectal cancer patients: safety and efficacy with analysis by age group

   • Esther Tahover
   • Ayala Hubert
   • Beatrice Uziely

   Original Research 06 March 2014 Pages: 55 - 63

   

6. Anticancer activity of the type I insulin-like growth factor receptor antagonist, ganitumab, in combination with the death receptor 5 agonist, conatumumab

   • Josep Tabernero
   • Sant P. Chawla
   • José Baselga

   Original Research 11 May 2014 Pages: 65 - 76

   

7. Expression and activity of EGFR in human cutaneous melanoma cell lines and influence of vemurafenib on the EGFR pathway

   • Alexander Gross
   • Annett Niemetz-Rahn
   • Alberto Fusi

   Original Research 15 May 2014 Pages: 77 - 84

   

8. Study on mouse model of triple-negative breast cancer: association between higher parity and triple-negative breast cancer

   • Chun Huang
   • Xuan Wang
   • Yan Li

   Original Research 17 May 2014 Pages: 85 - 97

   

9. A mutant BRAF V600E-specific immunohistochemical assay: correlation with molecular mutation status and clinical outcome in colorectal cancer

   • Fiona Day
   • Andrea Muranyi
   • Jayesh Desai

   Original Research Open access 27 May 2014 Pages: 99 - 109

   

10. Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

    • Irene Brana
    • Antonio Calles
    • Emiliano Calvo

    Original Research 15 June 2014 Pages: 111 - 123

    

11. Early skin toxicity predicts better outcomes, and early tumor shrinkage predicts better response after cetuximab treatment in advanced colorectal cancer

    • T. Kogawa
    • A. Doi
    • Y. Tsuji

    Original Research 27 May 2014 Pages: 125 - 133

    

12. Erlotinib in combination with pemetrexed/cisplatin for leptomeningeal metastases and cerebrospinal fluid drug concentrations in lung adenocarcinoma patients after gefitinib faliure

    • Haihong Yang
    • Xinyun Yang
    • Jianxing He

    Day-to-Day Practice 02 July 2014 Pages: 135 - 140

    

13. Idelalisib: a review of its use in chronic lymphocytic leukaemia and indolent non-Hodgkin’s lymphoma

    • Gillian M. Keating

    ADIS DRUG EVALUATION 01 February 2015 Pages: 141 - 151

    

14. Gefitinib: a review of its use in adults with advanced non-small cell lung cancer

    • Sohita Dhillon

    ADIS DRUG EVALUATION 01 February 2015 Pages: 153 - 170

    

15. Sorafenib: a review of its use in patients with radioactive iodine-refractory, metastatic differentiated thyroid carcinoma

    • Hannah A. Blair
    • Greg L. Plosker

    Adis Drug Evaluation 07 March 2015 Pages: 171 - 178